July 7th 2025
Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Bundled Payments and Other Cost-Management Approaches to Oncology Care
Responding to Patient Needs Central to Providing Value in Cancer Care
Cancer Trial Participants Can Successfully Self-Report Adverse Events